|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||3.7500 - 3.9500|
|52 Week Range||0.5480 - 4.9000|
|Beta (3Y Monthly)||4.85|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
CURE Pharmaceutical Holding Corp (OTC: CURR ) said Tuesday it managed to broaden its license from the U.S. Drug Enforcement Administration. The expanded license as an authorized manufacturer of Schedule ...
CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced it has broadened its U.S. Drug Enforcement Administration (DEA) license as an authorized manufacturer of Schedule 1 substances to include both cannabis plant extracts and synthetic cannabidiol (CBD). This license allows CURE to take advantage of its latest U.S. Patent No. 10,238,705 issuing this month for the extraction and purification of cannabis plant material, as well as subsequent processing of cannabis extracts for drug formulation. CURE will develop and manufacture cannabis-derived and synthetic cannabidiol-based pharmaceutical products using its CUREfilm™ technology at its facility in Oxnard, Calif. CUREfilm technology is ideal for the delivery of cannabinoids as it offers increased bioavailability, ease and precision of dosing and greater palatability.
CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced Ruben Jose King-Shaw Jr. has joined its Board of Directors. King-Shaw brings significant expertise in healthcare, government and finance. King-Shaw joins the recently named chairman William (Bill) Yuan and Dr. Gene Salkind, expanding the board to six.
CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced it has appointed William (Bill) Yuan to Chairman of the Board and Dr. Gene Salkind to its Board of Directors.
CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced that it will host an investor presentation at the Benzinga Cannabis Capital Conference at the Eden Roc Miami Beach Hotel in Miami on January 16, 2019 at 5pm. “This conference is the ideal kick-off to 2019, which is set to be a landmark year for the cannabis industry,” said Rob Davidson, CEO of CURE Pharmaceutical. If you would like to schedule a meeting with CURE Pharmaceutical, please contact Ashley Ray at email@example.com.
CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced it has tapped Alex Katz to be the company’s Chief Financial Officer. Bringing his expertise in venture capital, Katz will oversee the company’s financial functions and investment relations. “Our company is approaching 2019 amidst exponential growth and a clear vision to be a leader in drug delivery innovation,” said Robert Davidson, CEO and Chairman of the Board of CURE Pharmaceutical.
CURE Pharmaceutical (CURR), an innovative drug delivery and development company, has announced that the company secured a $2 million investment at $2.5 per share from Gene Salkind, a company advisor and biotech investor, bringing his total investment in the company to $3 million. In February 2018, Dr. Salkind joined CURE’s advisory board to help advance CURE’s pipeline for the central nervous system and other therapeutic areas. “This second round of financing from Dr. Salkind is an example of the confidence our investors see in the company’s future,” said Robert Davidson, CEO and Chairman of the Board of CURE Pharmaceutical.